A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #956

Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks.

Sidhu AS, Konig DJ, Yu-Corpuz BX, et al. International journal of dermatology. 2026.
Weak / noneOtherMentions: Melanotan II

Editor's note

This short commentary raises concern about social-media promotion of unregulated melanotan and the associated dermatologic and public-health risks. It is opinion and awareness-oriented rather than a data study, but it is directly on-topic for the melanotan safety and access narrative. Useful context for the risks of the unregulated market.

Plain-language abstract

A commentary highlights the dermatologic and public-health risks of unregulated melanotan use being promoted through social media.